ACADIA Pharmaceuticals Inc.

Total Valuation

ACADIA Pharmaceuticals Inc. carries a market capitalization of 3.80B, placing it among publicly traded companies globally. Its enterprise value stands at 3.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

ACADIA Pharmaceuticals Inc. currently has 172.13M shares outstanding.

Valuation Ratios

ACADIA Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 11.31. The price-to-sales ratio is 3.78, and the price-to-book ratio stands at 3.33.

Enterprise Valuation

On an enterprise value basis, ACADIA Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 35.29 and an EV/FCF ratio of 19.84. The EV/Sales ratio of 3.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 40.20 provides insight into valuation relative to core operating earnings.

Financial Position

ACADIA Pharmaceuticals Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, ACADIA Pharmaceuticals Inc. has paid -259.12M in income taxes, reflecting an effective tax rate of 40.86.

Stock Price Statistics

ACADIA Pharmaceuticals Inc.'s stock has gained approximately 4.57331% over the past 52 weeks. The 50-day moving average sits at 27.55, while the 200-day moving average is 24.60.

Income Statement

Over the trailing twelve months, ACADIA Pharmaceuticals Inc. generated 1.14B in revenue and converted that into 380.48M in net income, yielding earnings per share of 2.21. EBITDA reached 98.39M, while operating income came in at 86.37M.

Balance Sheet

ACADIA Pharmaceuticals Inc. holds 956.47M in cash and equivalents against 73.85M in total debt, resulting in a net debt position of -384.98M. Total book value stands at 1.31B, with working capital of 863.11M providing operational flexibility.

Cash Flow

ACADIA Pharmaceuticals Inc. produced 160.32M in operating cash flow over the past twelve months. After subtracting -14.69M in capital expenditures, free cash flow totaled 145.63M - equivalent to 0.86 per share.

Margins

ACADIA Pharmaceuticals Inc. operates with a gross margin of 91.13, reflecting its pricing power and cost economics. The operating margin of 7.59 and net profit margin of 33.42 provide insight into operational efficiency.

Dividends & Yields

Scores

ACADIA Pharmaceuticals Inc. posts an Altman Z-Score of 5.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.